What Is 2-amino-4-phosphonobutyric acid
Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.
Last updated: April 15, 2026
Key Facts
- AP4 was first synthesized in 1989 by researchers studying glutamate analogs
- Molecular weight is 209.12 g/mol with the formula C4H10NO5P
- Acts as a selective agonist for mGluR4, mGluR6, mGluR7, and mGluR8 receptors
- Used in studies of synaptic plasticity, pain, and neurodegenerative diseases
- Exhibits low blood-brain barrier permeability, limiting in vivo applications
Overview
2-Amino-4-phosphonobutyric acid (AP4) is a synthetic amino acid analog primarily used in neuropharmacological research. It functions as a selective agonist for specific subtypes of metabotropic glutamate receptors, particularly those in group III, which play roles in regulating neurotransmitter release.
Developed to mimic the structure of glutamate while resisting enzymatic degradation, AP4 helps scientists study inhibitory signaling in the central nervous system. Its phosphonate group enhances stability compared to natural amino acids, making it valuable for in vitro experiments.
- Chemical formula: C4H10NO5P, with a molecular weight of 209.12 g/mol, enabling precise dosing in laboratory settings.
- First synthesized in 1989 by Japanese researchers exploring glutamate receptor subtypes, marking a key advancement in neurochemical tools.
- Acts as a selective agonist for mGluR4, mGluR6, mGluR7, and mGluR8, distinguishing it from broader-acting glutamate analogs.
- Exhibits low permeability across the blood-brain barrier, limiting its use to controlled in vitro or intracerebral administration studies.
- Used to investigate conditions like epilepsy, chronic pain, and Parkinson’s disease, where glutamate signaling is dysregulated.
How It Works
AP4 modulates synaptic activity by selectively activating group III metabotropic glutamate receptors (mGluRs), which are primarily located presynaptically and function to inhibit neurotransmitter release. Its mechanism involves binding to specific receptor subtypes and initiating intracellular signaling cascades.
- Group III mGluRs: AP4 binds to mGluR4, mGluR6, mGluR7, and mGluR8, reducing calcium influx and suppressing neurotransmitter release in neurons.
- Phosphonate group: The phosphorus-containing moiety resists hydrolysis, increasing the compound’s stability and prolonging its action in tissue preparations.
- EC50 value: For mGluR4 activation, AP4 has an EC50 of approximately 1.2 μM, indicating high potency at this receptor subtype.
- Synaptic inhibition: By activating presynaptic mGluRs, AP4 reduces glutamate and GABA release, helping to dampen excessive neural activity in seizure models.
- Receptor specificity: Unlike AP3 or glutamate itself, AP4 shows minimal activity at ionotropic receptors or group I/II mGluRs.
- In vitro applications: Commonly used in brain slice preparations at concentrations between 10–100 μM to study synaptic plasticity and network dynamics.
Comparison at a Glance
The following table compares AP4 with related glutamate analogs in terms of receptor affinity, molecular properties, and research applications.
| Compound | Primary Target | Molecular Weight (g/mol) | BBB Permeability | Common Use |
|---|---|---|---|---|
| AP4 | mGluR4/6/7/8 | 209.12 | Low | Neurotransmitter inhibition studies |
| AP3 | mGluR3, mGluR4 | 195.10 | Low | Early mGluR research |
| L-AP4 | mGluR6 | 209.12 | Low | Retinal signaling research |
| Glutamate | All glutamate receptors | 147.13 | High | General excitatory neurotransmission |
| LY354740 | mGluR2/3 | 209.22 | High | Anxiety and schizophrenia models |
This comparison highlights AP4’s niche as a selective group III mGluR agonist. While other compounds like LY354740 cross the blood-brain barrier more effectively, AP4 remains valuable for targeted in vitro work due to its specificity and stability.
Why It Matters
Understanding how AP4 influences neural circuits provides insight into the regulation of excitatory signaling, which is critical in both normal brain function and neurological disorders. Its use in research continues to inform drug development for conditions involving glutamate dysregulation.
- Neurological research: AP4 helps dissect the role of mGluRs in diseases like epilepsy and Parkinson’s, where excessive glutamate activity is pathological.
- Pain modulation: Activation of mGluR4 by AP4 reduces pain signaling in spinal cord models, suggesting therapeutic potential for chronic pain.
- Drug development: Serves as a template for designing more stable, brain-penetrant mGluR agonists with clinical applications.
- Retinal studies: L-AP4 (a stereoisomer) is used to isolate bipolar cell function in the retina by blocking glutamate release.
- Limitations: Poor oral bioavailability and short half-life restrict its use to experimental settings, not clinical therapy.
- Future potential: Derivatives of AP4 are being explored for neuroprotective effects in stroke and neurodegenerative diseases.
Despite its experimental limitations, AP4 remains a cornerstone tool in neuroscience for probing the function of inhibitory glutamate pathways.
More What Is in Daily Life
Also in Daily Life
More "What Is" Questions
Trending on WhatAnswers
Browse by Topic
Browse by Question Type
Sources
- WikipediaCC-BY-SA-4.0
Missing an answer?
Suggest a question and we'll generate an answer for it.